# A hybrid type III effectiveness-implementation, pragmatic intervention trial for cervical cancer screen and treat in Mozambique

> **NIH NIH U01** · TULANE UNIVERSITY OF LOUISIANA · 2024 · $643,363

## Abstract

PROJECT SUMMARY AND ABSTRACT
Every year approximately 300,000 women die from cervical cancer, with over 90% of those deaths occurring in
low-and middle-income countries (LMICs).1 The majority of cervical cancers are preventable through vaccination
against high-risk types of human papillomavirus (HPV), the virus that causes nearly all cervical cancers, or by
screening for and treatment of precancerous lesions among women already infected with HPV. In 2021, the
WHO recommended HPV testing among women aged 25-49 years for all cervical cancer screening programs
worldwide.3 Despite this recommendation, access to affordable HPV testing remains a barrier, and to date, there
is limited field experience with HPV testing across sub-Saharan Africa (SSA). HPV self-sampling holds great
promise in improving access to screening and promoting equity by increasing control over where, when, and
how women are screened. Preliminary data from two recent studies conducted by MD Anderson in Mozambique
have shown that cervical cancer screening with HPV DNA testing is feasible in Mozambique and that participants
in the study preferred self-collection approaches.11,12 Guided by the Knowledge-to-Action conceptual framework,
which was designed to enhance uptake of evidence-based practice into clinical care, we propose a hybrid type
III effectiveness – implementation trial to test implementation best practices of deploying the Screen & Treat
approach to cervical cancer screening utilizing self-collected HPV DNA testing within HIV care and treatment of
select health facilities. This proposal directly addresses the ability to safely scale-up a Screen & Treat approach
to cervical cancer screening. We propose to capitalize on a pool of screen-eligible women accessing routine
care within targeted HIV care and treatment services. The primary outcome of interest is the number of women
screened and the number of screen-positive women undergoing treatment. Secondary outcomes will focus on
other implementation outcomes, and if successful, will be utilized to inform future research to take this approach
to scale across Mozambique.

## Key facts

- **NIH application ID:** 11000924
- **Project number:** 1U01CA294674-01
- **Recipient organization:** TULANE UNIVERSITY OF LOUISIANA
- **Principal Investigator:** D. Troy Moon
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $643,363
- **Award type:** 1
- **Project period:** 2024-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11000924

## Citation

> US National Institutes of Health, RePORTER application 11000924, A hybrid type III effectiveness-implementation, pragmatic intervention trial for cervical cancer screen and treat in Mozambique (1U01CA294674-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11000924. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*